New Clinical Trial Explores GIP's Long-Term Effects on Bone Health and Remodeling

The Glucose-dependent Insulinotropic Polypeptide (GIP) is a hormone released by the gut after eating, primarily known for stimulating insulin secretion. Previous research has shown that short-term GIP exposure (< 3 hours) can decrease bone resorption (the process of breaking down bone tissue) in humans. However, this beneficial effect appears to diminish with continuous administration over 24 hours, particularly in patients with type 1 diabetes. Given the recent approval of tirzepatide, a GIP receptor (GIPR) agonist, for treating obesity and type 2 diabetes, there's a critical need to understand the long-term impact of GIP on bone health. This study specifically addresses whether the anti-resorptive effect of GIP can be maintained through non-continuous administration and how different GIP exposure times affect the skeleton.

As a recruiting clinical trial, the GINEBRA study has not yet yielded results; however, it aims to establish crucial findings regarding GIP's impact on bone health. The researchers hypothesize that by utilizing a non-continuous administration approach, GIP's anti-resorptive effects on bone can be sustained over the long term, unlike previous observations with continuous exposure. The study expects to quantify changes in bone turnover markers (indicators of bone formation and breakdown), potentially showing a significant reduction in resorption markers and maintenance or improvement in formation markers. They will also assess bone mineral density (BMD) and other structural parameters to determine if GIP can positively influence overall bone strength and integrity. The primary objective is to determine if non-continuously administered Glucose-dependent Insulinotropic Polypeptide (GIP) can maintain its anti-resorptive effect on bone, potentially leading to a significant improvement in bone health outcomes compared to control groups.